AB
CMPX icon

Amalgamated Bank’s Compass Therapeutics CMPX Stock Holding History

Amalgamated Bank’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,111
Closed -$22K – 1881
2025
Q4 		$22K Buy
4,111
+1,034
+34% +$4.78K ﹤0.01% 2061
2025
Q3 		$11K Hold
3,077
– – ﹤0.01% 2411
2025
Q2 		$8K Hold
3,077
– – ﹤0.01% 2519
2025
Q1 		$6K Hold
3,077
– – ﹤0.01% 2569
2024
Q4 		$4K Hold
3,077
– – ﹤0.01% 2775
2024
Q3 		$6K Hold
3,077
– – ﹤0.01% 2680
2024
Q2 		$3K Hold
3,077
– – ﹤0.01% 2906
2024
Q1 		$6K Sell
3,077
-5,384
-64% -$9.3K ﹤0.01% 2631
2023
Q4 		$13K Sell
8,461
-916
-10% -$1.58K ﹤0.01% 2800
2023
Q3 		$18K Hold
9,377
– – ﹤0.01% 2700
2023
Q2 		$30K Buy
+9,377
New +$29.4K ﹤0.01% 2524

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Amalgamated Bank's CMPX Position: Q1 2026 in Review

Amalgamated Bank sold out of Compass Therapeutics (CMPX) in Q1 2026, closing a stake of 4,111 shares — an estimated $22K sold.

Amalgamated Bank first reported a position in CMPX in Q2 2023 and held it in 11 quarters. The position peaked at $30K in Q2 2023. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Amalgamated Bank reported no remaining Compass Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 4,111 Compass Therapeutics shares in Q1 2026, an estimated $22K.
  • Amalgamated Bank first reported a position in Compass Therapeutics in Q2 2023 and held it in 11 quarters.
  • Amalgamated Bank's Compass Therapeutics position peaked at $30K in Q2 2023.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.